Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.

Transactions of the American Clinical and Climatological Association - 1 Jan 2009

Davignon Jean, Dubuc Geneviève

Abstract excerpt

PCSK9 is a natural inhibitor of the LDL receptor. Gain-of-function mutations may cause the familial hypercholesterolemia phenotype, whereas loss-of-function variants associate with reduced LDL-C levels and lower coronary risk. Statins up-regulate PCSK9 in hepatocytes. We developed an assay to measure total PCSK9 in human plasma and evaluated the effect of statins and ezetimibe on PCSK9 in vivo and in vitro. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Atorvastatin
Share to Azetidines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caco-2 Cells

Share to Ezetimibe

Share to Heptanoic Acids

Share to Proprotein Convertase 9

Share to Proprotein Convertases

Source

Open in PubMed Open full text

Identifiers

PMID: 19768174
PMCID: PMC2744528

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.PMID 19768174Read ↗

Clinical aspects of PCSK9.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.Semantic proximity Read ↗

The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Semantic proximity Read ↗

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.Semantic proximity Read ↗

The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.Semantic proximity Read ↗

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.Semantic proximity Read ↗

PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes.Semantic proximity Read ↗

PCSK9: a key modulator of cardiovascular health.Semantic proximity Read ↗

Targeting PCSK9 for the treatment of hypercholesterolemia.Semantic proximity Read ↗

The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications.Semantic proximity Read ↗

Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition.Semantic proximity Read ↗

Unravelling the functional significance of PCSK9.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.